University at Buffalo - The State University of New York
Skip to Content

Faculty and Staff Directory

Donald                         Mager

Donald E. Mager Pharm.D., Ph.D., FCP

Department of Pharmaceutical Sciences

Professor and Vice Chair

 
Professional Summary:

Research interest areas:

1. Integrative and Systems Pharmacology of Anti-Platelet and Anti-Cancer Drugs

2. Development and experimental validation of quantitative structure-pharmacokinetic/pharmacodynamic (PK/PD) relationships (QSPR) to optimize drug design, development, and therapeutic application of anti-cancer compounds.

3. Integration of QSPR and mechanistic PD models developed with several drugs to predict in vivo PK/PD profiles of chemically related compounds.

4. Development of models of pharmacological target-mediated drug disposition and dynamics, and the experimental validation of the primary determinants of PK/PD profiles of drugs that exhibit such phenomena.

5. Development of non-deterministic models such as neural networks, alone or in combination with traditional adaptive feedback control methods, for individual optimization of complex pharmacotherapeutic regimens.

6. Incorporation of biomedical signal processing tools into PK/PD models for characterizing the pharmacology of drugs that alter spontaneous variability of signals of the cardiovascular and autonomic nervous systems

Education and Training:
  • PhD, Pharmaceutical Sciences, University at Buffalo, State University of New York (2002)
  • PharmD, Pharmacy, University at Buffalo, State University of New York (2000)
  • BS, Pharmacy, University at Buffalo, State University of New York (1991)
Employment:
  • Professor, Pharmaceutical Sciences, University at Buffalo, SUNY (2016-present)
  • Associate Professor, Pharmaceutical Sciences, University at Buffalo, State University of New York (2010–2016)
  • Assistant Professor, Pharmaceutical Sciences, University at Buffalo, State University of New York (2004–2010)
  • IRTA Post-Doctoral Fellow, National Intitute on Aging (2002–2004)
Awards and Honors:
  • Visiting Professor (2013)
  • Visiting Professor (2012)
  • Visiting Professor (2011)
  • Visiting Professor (2010)
  • Fellow (2009)
  • Visiting Professor (2009)
  • Teacher of the Year Award Finalist (2008)
  • Visiting Professor (2008)
  • New Investigator Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (2007)
  • Visiting Professor (2007)
  • University at Buffalo Young Investigator Award (2006)
  • American Foundation for Pharmaceutical Education Pre-doctoral Fellowship (2002)
  • Eli Lilly and Company Graduate Symposium in Pharmacokinetics, Pharmacodynam (2002)
  • Who’s Who Among Students in American Universities and Colleges (2002)
  • American Foundation for Pharmaceutical Education Pre-doctoral Fellowship (2001)
  • PPDM Travel Award Winner (2001)
  • University at Buffalo Pharmaceutical Sciences Graduate Scholar Award (2001)
  • American Foundation for Pharmaceutical Education Pre-doctoral Fellowship (2000)
  • University Woodburn/Presidential Fellowship (1999)


Journal Articles:
  • Nanavati C, Mager DE. Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells. Pharm Res. 2017; 34(3).
  • Cirincione B, Edwards J, Mager DE. Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration. AAPS J. 2016.
  • Li H, Mager DE, Sandmaier BM, Storer BE, Boeckh MJ, Bemer MJ, Phillips BR, Risler LJ, McCune JS. Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil. Biol Blood Marrow Transplant. 2014; 20(8).
  • Bruno R, Mentré F, Tannenbaum S, Wang Y, Corrigan B, Mager DE. The ISoP Standards and Best Practices Committee. Clin Pharmacol Ther. 2014; 95(6).
  • Kagan L, Zhao J, Mager DE. Interspecies Pharmacokinetic Modeling of Subcutaneous Absorption of Rituximab in Mice and Rats. Pharm Res. 2014.
  • Liu ZJ, Hoffmeister KM, Hu Z, Mager DE, Ait-Oudhia S, Debrincat MA, Pleines I, Josefsson EC, Kile BT, Italiano J, Ramsey H, Grozovsky R, Veng-Pedersen P, Chavda C, Sola-Visner M. Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. Blood. 2014; 123(22).
  • Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV. Soy Phosphatidylinositol Containing Nanoparticle Prolongs Hemostatic Activity of B-Domain Deleted Factor VIII in Hemophilia A Mice. J Pharm Sci. 2014.
  • Kosloski MP, Pisal DS, Mager DE, Balu-Iyer SV. Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. Biopharm Drug Dispos. 2014; 35(3).
  • Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE. Population-based meta-analysis of furosemide pharmacokinetics. Biopharm Drug Dispos. 2014; 35(2).
  • Kagan L, Gershkovich P, Wasan KM, Mager DE. Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition. Pharm Res. 2014; 31(1).
  • Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE. Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. Biopharm Drug Dispos. 2013; 34(9).
  • Harrold JM, Ramanathan M, Mager DE. Network-based approaches in drug discovery and early development. Clin Pharmacol Ther. 2013; 94(6).
  • Chen T, Kagan L, Mager DE. Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats. J Pharm Sci. 2013; 102(10).
  • Hong Y, Dingemanse J, Sidharta P, Mager DE. Population pharmacodynamic modeling of hyperglycemic clamp and meal tolerance tests in patients with type 2 diabetes mellitus. AAPS J. 2013; 15(4).
  • Birtwistle MR, Mager DE, Gallo JM. Mechanistic vs. Empirical network models of drug action. CPT Pharmacometrics Syst Pharmacol. 2013; 2.
  • Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE. Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis. Biopharm Drug Dispos. 2013; 34(6).
  • McDermott CL, Sandmaier BM, Storer B, Li H, Mager DE, Boeckh MJ, Bemer MJ, Knutson J, McCune JS. Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013; 19(8).
  • Kosloski M; Pisal D; Mager DE; Balu-Iyer SV. Allometry of Factor VIII and informed scaling of next generation therapeutic proteins. Journal of Pharmaceutical Sciences. 2013.
  • Jiang XL; Shen HW; Mager DE; Yu A. Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status. Drug Metab Dispos. 2013; 41.
  • Li H; Mager DE; Sandmaier BM; Maloney DG; Bemer MJ; McCune JS. Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol. 2013; 53.
  • Chen T; Mager DE; Kagan L. Interspecies modeling and prediction of human exenatide pharmacokinetics. Pharm Res. 2013; 30.
  • Ait-Oudhia S; Straubinger RM; Mager DE. Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy. J Pharmacol Exp Ther. 2013; 344.
  • Kagan L, Mager DE. Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab Dispos. 2013; 41(1).
  • Li H; Mager DE; Bemer MJ; Salinger DH; Vicini P; Sandmaier BM; Nash R; McCune JS. A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentration-Time Curve in Hematopoietic Cell Transplantation Recipients. J Clin Pharmacol. 2012; 52.
  • Marathe A; Iyer S; Qiu J; Visich J; Mager DE. Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in mice. Pharm Res. 2012; 29.
  • Ait-Oudhia S; Straubinger RM; Mager DE. Meta-analysis of Nanoparticulate Paclitaxel Delivery System Pharmacokinetics and Model Prediction of Associated Neutropenia. Pharm Res. 2012; 29.
  • Chudasama V. L., Schaedeli-Stark F., Harrold J. M., Tibbitts J., Girish S. R., Gupta M., Frey N., Mager DE. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther. 2012; 92.
  • Ait-Oudhia S; Lowe PJ; Mager DE. Bridging clinical outcomes of canakinumab treatment in rheumatoid arthritis patients with a population model of IL-1beta kinetics. CPT:Pharmacomet Syst Pharmacol. 2012; 1.
  • Mager DE; Mody V; Xu C; Forrest A; Lesniak WG; Nigavekar SS; Minc L; Khan MK; Balogh LP. Physiologically based pharmacokinetic model for composite nanodevices: effect of charge and size on in vivo disposition. Pharm Res. 2012; 29.
  • Zhao X; Venkata SL; Moaddel R; Luckenbaugh DA; Ibrahim L; Zarate Jr. CA; Mager DE; Wainer IW. Simultaneous Population Pharmacokinetic Modeling of Ketamine and Three Major Metabolites in Patients with Treatment-Resistant Bipolar Depression. BJCP. 2012; 74.
  • Harrold JM; Straubinger RM; Mager DE. Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. Cancer Res. 2012; 72.
  • Katrissios H; Walker JR; Carrothers TJ; Kshirsagar S; Khariton T; Habtemariam B; Mager DE; Rohatagi S. Population Pharmacokinetic Model for a Novel Oral Hypoglycemic Formed In Vivo: Comparing the Use of Active Metabolite Data Alone Versus Using Data of Upstream and Downstream Metabolites. J Clin Pharmacol. 2012; 52.
  • Iyengar R; Zhao S; Chung S; Mager DE; Gallo JM. Merging systems biology with pharmacodynamics. Science Translational Medicine. 2012; 4.
  • Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM. Merging systems biology with pharmacodynamics. Sci Transl Med. 2012; 4(126).
  • Kagan L; Turner M; Balu-Iyer SV; Mager DE. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res. 2012; 29.
  • Felmlee MA, Morris ME, Mager DE. Mechanism-based pharmacodynamic modeling. Methods Mol Biol. 2012; 929.
  • Marathe DD; Marathe A; Mager DE. Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. Biopharmaceutics & Drug Disposition. 2011; 32.
  • Abraham AK; Maurer TS; Kalgutkar AS; Gao X; Li M; Healy DR; Petersen DN; Griffith DA; Mager DE. Pharmacodynamic model of parathyroid hormone modulation by a negative allosteric modulator of the calcium-sensing receptor. AAPS J. 2011; 13.
  • Kagan L; Gershkovich P; Wasan KM; Mager DE. Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (fungizoner): pooled analysis of published data. AAPS J. 2011; 13.
  • Kosloski M; Peng A; Varma P; Miclea RD; Mager DE; Balu-Iyer SV. Immunogenicity and pharmacokinetic studies of recombinant Factor VIII containing lipid cochleates. Drug Delivery. 2011; 8 (20.
  • Marathe A; Van Wart S; Mager DE. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2011; 38.
  • Goldberg ME; Torjman MC; Schwartzman RJ; Mager DE; Wainer IW. Enantioselective pharmacokinetics of (R)- and (S)-ketamine after a 5-day infusion in patients with complex regional pain syndrome. Chirality. 2011; 23.
  • Xu C, Mager DE. Quantitative structure-pharmacokinetic relationships. Expert Opin Drug Metab Toxicol. 2011; 7(1).
  • Yan X; Mager DE; Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.. Journal of Pharmacokinetics and Pharmacodynamics. 2010.
  • D'Argenio DZ; Mager DE. Bridging pharmacology and pathophysiology via systems modeling. J Clin Pharmacol. 2010; 50.
  • Kagan L; Dreifinger T; Mager DE; Hoffman A. Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. Drug Metab Dispos. 2010; 38.
  • Houze P; Mager DE; Risede P; Baud FJ. Pharmacokinetics and toxicodynamics of pralidoxime effects on paraoxon-induced respiratory toxicity. Toxicol Sci. 2010; 116.
  • Goldberg ME; Torjman MC; Schwartzman RJ; Mager DE; Wainer IW. Pharmacodynamic profiles of ketamine (R)- and (S)- with 5-day inpatient infusion for the treatment of complex regional pain syndrome. Pain Physician. 2010; 13.
  • Abraham AK; Kagan L; Kumar S; Mager DE. Type I Interferon Receptor is a Primary Regulator of Target-mediated Drug Disposition of Interferon-{beta} in Mice. J Pharmacol Exp Ther. 2010; in pr.
  • Kagan L; Abraham AK; Harrold JM; Mager DE. Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res. 2010; 27.
  • Siluk D; Mager DE; Kim HS; Wang Y; Furimsky AM; Ta A; Iyer LV; Green CE; Wainer IW. Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in rat. Xenobiotica. 2010; 40.
  • Siluk D, Mager DE, Kim HS, Wang Y, Furimsky AM, Ta A, Iyer LV, Green CE, Wainer IW. Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in rat. Xenobiotica. 2010; 40(3).
  • Dhindsa S; Miller MG; McWhirter CL; Mager DE; Ghanim H; Chaudhuri A; Dandona P. Testosterone Concentrations in Diabetic and Non-Diabetic Obese Men. Diabetes Care. 2010; 33.
  • Yang J; Mager DE; Straubinger RM. Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. AAPS Journal. 2010; 12.
  • Zhou R; Mazurchuk RV; Tamburlin JH; Harold JM; Mager DE; Straubinger RM. Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model. J Pharmacol Exp Ther. 2010; 332.
  • Xu C, Barchet TM, Mager DE. Quantitative structure–property relationships of camptothecins in humans. Cancer Chemother Pharmacol. 2010; 65(2).
  • Hilmer SN; Mager DE; Simonsick EM; Ling SM; Windham BG; Harris TB; Shorr RI; Bauer DC; Abernethy DR. Drug burden index score and functional decline in older people. Am J Med. 2009; 122.
  • Abraham AK; Ramanathan M; Weinstock-Guttman B; Mager DE. Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol. 2009; 77.
  • Marathe A; Krzyzanski W; Mager DE. Numerical Validation and Properties of a Rapid Binding Approximation of a Target-Mediated Drug Disposition Pharmacokinetic Model. J Pharmacokinet Pharmacodyn. 2009; 36.
  • Abraham AK; Mager DE; Gao X; Li M; Healy DR; Maurer TS. Mechanism-based pharmacokinetic/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans J Pharmacol Exp Ther. 2009; 330.
  • Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet. 2009; 24(1).
  • Marathe A; Peterson MC; Mager DE. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther. 2008; 326.
  • Hong Y; Dingemanse J; Mager DE. Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren. Clin Pharmacol Ther. 2008; 84.
  • Mager DE; Jusko WJ. Development of Translational Pharmacokinetic-Pharmacodynamic Models. Clin. Pharmacol. Ther.. 2008; 83.
  • Hong Y; Rohatagi S; Habtemariam B; Walker JR; Schwartz SL; Mager DE. Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol. 2008; 48.
  • Ramani K; Miclea RD; Purohit VS; Straubinger RM; Mager DE; Balu-Iyer SV. Phosphatidylserine Containing Liposomes reduce Immunogenicity of Recombinant Human Factor VIII in a Murine Model of Hemophilia A. Journal. Pharmaceutical Sciences. 2008; 97.
  • Cao YJ; Abernethy DR; Mager DE; Simonsick EM; Hilmer SN; Ling SM; Windham BG; Crentsil V; Yasar S; Fried LP. Physical and Cognitive Performance and Burden of Anticholinergics, Sedatives, and ACE Inhibitors in Older Women. Clin Pharmacol Ther. 2008; 83.
  • Gengo FM, Rubin L, Robson M, Rainka M, Gengo MF, Mager DE, Bates V. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol. 2008; 48(1).
  • Gengo FM; Rubin L; Robson M; Rainka M; Mager DE; Bates V. Effects of Ibuprofen on the Magnitude and Duration of Aspirin`s Inhibition of Platelet Aggregation: Clinical Consequences in Stroke Prophylaxis. J Clin Pharmacol. 2008; 48.
  • Hong Y; Gengo FM; Rainka MN; Bates VE; Mager DE. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Clin Pharmacokinet. 2008; 47.
  • Siluk D; Mager DE; Gronich N; Abernethy DR; Wainer IW. HPLC-atmospheric pressure chemical ionization mass spectrometric method for enantioselective determination of R,S-propranolol and R,S-hyoscyamine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 859.
  • Mager DE; Kobrinsky E; Masoudieh A; Maltsev A; Abernethy DR; Soldatov NM. Analysis of functional signaling domains from fluorescence imaging and the two-dimensional continuous wavelet transform. Biophys J. 2007; 93.
  • Abraham AK, Krzyzanski W, Mager DE. Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition. AAPS J. 2007; 9(2).
  • Abraham AK; Krzyzanski W; Mager DE. Partial derivative based sensitivity analysis of models describing target-mediated drug disposition. AAPS J. 2007; 9.
  • Hong Y; Mager DE; Blum RA; Jusko WJ. Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: Modeling interoccasion pharmacodynamic variability. Pharm Res. 2007; 24.
  • Mager DE; Abernethy DR. Use of wavelet and fast Fourier transforms in pharmacodynamics. J Pharmacol Exp Ther. 2007; 321.
  • Hilmer SN; Shorr RI; Bauer DC; Abernethy DR; Mager DE; Simonsick EM; Cao Y; Ling SM; Windham G; Harris TB; Hanlon JT; Rubin SM. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007; 167.
  • O'Connor R; Kennedy S; Fennelly D; Clynes M; Crown J; O'Leary M; Ballot J; Collins CD; Kinsella P; Mager DE; Arnold RD; O'Driscoll L; Larkin A. A phase I clinical and pharmacokinetic study of the multidrug resistance protein-1 (MRP-1) inhibitor sulindac in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol. 2007; 59.
  • Mager DE. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Adv Drug Deliv Rev. 2006; 58.
  • Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol. 2006; 72.
  • Mager DE; Wan R; Brown M; Cheng A; Abernethy DR; Mattson MP. Caloric restriction and intermittent fasting alter spectral measures of heart rate and blood pressure variability in rats. FASEB J. 2006; 20.
  • Arnold RD; Mager DE; Slack JE; Straubinger RM. Effect of repetitive administration of doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin Cancer Res. 2005; 11.
  • Mager DE; Shirey JD; Cox D; Fitzgerald DJ; Abernethy DR. Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network. J Pharm Sci. 2005; 94.
  • Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005; 22(10).
  • Kobrinsky E, Mager DE, Bentil SA, Murata S, Abernethy DR, Soldatov NM. Identification of plasma membrane macro- and microdomains from wavelet analysis of FRET microscopy. Biophys J. 2005; 88(5).
  • Mager DE; Neuteboom B; Jusko WJ. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res. 2005; 22.
  • Mager DE; Abernethy DR; Egan JM; Elahi D. Exendin-4 pharmacodynamics: Insights from the hyperglycemic clamp technique. J Pharmacol Exp Ther. 2004; 311.
  • Williams ML; Mager DE; Parenteau H; Gudi G; Tracy TS; Mulheran M; Wainer IW. Effects of protein calorie malnutrition on the pharmacokinetics of ketamine in rats. Drug Metab Disp. 2004; 32.
  • Anderton MJ; Manson MM; Verschoyle R; Gescher A; Steward WP; Williams ML; Mager DE. Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Disp. 2004; 32.
  • Segrave AM, Mager DE, Charman SA, Edwards GA, Porter CJ. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J Pharmacol Exp Ther. 2004; 309(3).
  • Urquidi-Macdonald M; Mager DE; Mascelli MA; Frederick B; Freedman J; Fitzgerald DJ; Kleiman NS; Abernethy DR. Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. Clin Pharmacol Ther. 2004; 75.
  • Mager DE; Mascelli MA; Kleiman NS; Fitzgerald DJ; Abernethy DR. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther. 2003; 307.
  • Mager DE; Lin SX; Blum RA; Lates CD; Jusko WJ. Dose equivalency evaluation of major corticosteroids: Pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol. 2003; 43.
  • Wyska E; Mager DE; Krzyzanski W. Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. J Pharm Sci. 2003; 92.
  • Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther. 2003; 306(1).
  • Mager DE; Neuteboom B; Efthymiopoulos C; Munafo A; Jusko WJ. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta 1a in monkeys. J Pharmacol Exp Ther. 2003; 306.
  • Mager DE; Moledina N; Jurek SJ. Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. J Pharm Sci. 2003; 92.
  • Levy G; Mager DE; Cheung WK; Jusko WJ. Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci. 2003; 92.
  • Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003; 31(5).
  • Mager DE; Pyszczynski NA; Jusko WJ. Integrated QSPR - pharmacodynamic model of genomic effects of several corticosteroids. J Pharm Sci. 2003; 92.
  • Mager DE; Jusko WJ. Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. J Pharm Sci. 2002; 91.
  • Mager DE; Jusko WJ. Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in man. Pharm Res. 2002; 19.
  • Mager DE, Jusko WJ. Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans. Pharm Res. 2002; 19(10).
  • Mager DE; Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001; 28.
  • Mager DE; Jusko WJ. Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther. 2001; 70.
See all (95 more)
Books and Book Chapters:
  • Mager DE. Application of pharmacokinetic/pharmacodynamic modeling in the development of antibody-based therapeutics. Development of Antibody-Based Therapeutics. 2012.
  • Van Wart SA; Mager DE. Clinical pharmacokinetics and pharmacodynamics of stereoisomeric drugs. Drug Stereochemistry: Analytical Methods and Pharmacology. 2012.
  • Van Wart SA; Mager DE. Clinical pharmacokinetics and pharmacodynamics of stereoisomeric drugs. Drug Stereochemistry: Analytical Methods and Pharmacology. 2012.
  • Felmlee MA; Morris ME; Mager DE. Mechanism-based pharmacodynamic modeling. Computational Toxicology. 2012; 1.
  • Balogh L; Mager DE; Khan MK. Synthesis and biodisposition of dendrimer composite nanoparticles. Handbook of Materials for Nanomedicine. 2010.
  • Mager DE; Jusko WJ. Mechanistic Pharmacokinetic/Pharmacodynamic Models II (Chapter 23). Pharmacometrics, The Science of Quantative Pharmacology. 2007.
  • Mager DE; Ramanathan M. Preclinical Pharmacokinetics. Handbook of Pharmaceutical Biotechnology. 2007.

Professional Memberships:
  • International Pharmaceutical Federation (2012)
  • American Association for Cancer Research (2012)
  • International Society of Pharmacometrics (2011)
  • American Association of Colleges of Pharmacy (2005)
  • Association of Colleges of Pharmacy (2005–present)
  • American Society for Pharmacology and Experimental Therapeutics (2004)
  • American College of Clinical Pharmacology (2004)
  • American College of Clinical Pharmacology (2004–present)
  • American Society for Pharmacology and Experimental Therapeutics (2004–present)
  • American Society for Clinical Pharmacology and Therapeutics (2003)
  • American Association for the Advancement of Science (2003)
  • American Association for the Advancement of Science (2003–present)
  • American Society for Clinical Pharmacology and Therapeutics (2003–present)
  • American Association of Pharmaceutical Scientists - UB Student Chapter; 1999-2002 Chair (Sept. 2000-Sept. 2001), Vice-Chair (Sept. 1999-Sept. 2000) (1999–2001)
  • Graduate Student Association Department of Pharmaceutical Sciences; Chair (May 1999 - May 2000) (1999–2002)
  • Graduate Student Association; Chair (5/99 - 5/00) (1999)
  • American Association of Pharmaceutical Scientists (1999)
  • American Association of Pharmaceutical Scientists (1999–present)
See all (8 more)
Presentations:
  • "Integrated Network and Systems Pharmacology Modeling and US Initiatives" EUFEPS Workshop: Systems Pharmacology - Towards a European Network?, EUFEPS (2013)
  • "Pharmacodynamic Modeling of Heart Rate Variability (HRV) and Vagal Tone" ACOP Annual Meeting, ISOP (2013)
  • "Semi-Mechanistic Population Pharmacokinetic Approaches for ADCs" Short-course: ADCs in Clinical Development: Initiating Phase I and Beyond, AAPS NBC (2013)
  • "Utilizing Semi-mechanistic Pharmacokinetic Models for Improved ADC Development" AAPS NBC Annual Meeting, AAPS (2013)
  • "Translational Pharmacodynamic Modeling of Combinatorial Therapy in Oncology" , University of Toronto (2013)
  • "PK/PD Aspects of Targeted Covalent Drugs" Delaware Valley Drug Metabolism Discussion Group Meeting, DVDMDG (2013)
  • "Theoretical, Translational and Technical Capabilities in Applying Quantitative Approaches to Combination Therapy" ASCPT Annual Meeting, ASCPT (2013)
  • "Translational Pharmacodynamic Modeling of Combinatorial Therapeutic Systems" Pre-Conference: Quantitative Systems Pharmacology: An Integrating Framework for Translational Medicine, ASCPT (2013)
  • "Computational Coupling of Signal Transduction and Pharmacodynamic Systems" Workshop: Systems Pharmacology for the Prediction of Tyrosine Kinase Inhibitor non-QT Cardiotoxicity, Co-convened by Reagan-Udall Foundation & Food and Drug Administration (2013)
  • "Pharmacometric Analysis of Nanoparticulate and Antibody-Based Anti-Cancer Agents" , National Institute for Cellular Biotechnology, Dublin City University (2012)
  • "PK/PD Systems Analysis of Biologics" PKUK Annual Meeting, PKUK (2012)
  • "Translational PK/PD Analysis of Nanoparticulate and Antibody-Based Anti-Cancer Agents" Indiana Clinical and Translational Sciences Institute Symposium on Disease and Therapeutic Response Modeling, University of Indiana (2012)
  • "Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans" AAPS Annual Meeting, AAPS (2012)
  • "Applications of Quantitative Pharmacology: PK/PD M&S for Identifying Optimal Biologic Dose" ACCP Annual Meeting, ACCP (2012)
  • "Potential Mechanisms of Drug-Drug Interactions with Therapeutic Proteins" ACCP Annual Meeting, ACCP (2012)
  • "Pharmacokinetic/pharmacodynamic modeling of cocaine self-administration behavior in rats" 74th Annual Meeting - College on Problems of Drug Dependence, The College on Problems of Drug Dependence (CPDD) (2012)
  • "Towards Integrating Systems Pharmacology and Pharmacodynamic Modeling in Oncology" Applications of Systems Biology to Drug Discovery & Development, Roche (2012)
  • "Translational Pharmacometrics: Integration of Systems Pharmacology and PK/PD Modeling" Pharmacometrics: Modeling and simulation in Drug Development, Center for Human Experimental Therapeutics, University of Rochester Medical Center (2012)
  • "Pharmacokinetics & Pharmacodynamics of Biological Therapeutics" Msc Program, University of Manchester (2012)
  • "Mathematical Analysis of Paclitaxel-induced Tumor Priming That Leads to Enhanced Deposition and Efficacy of Nanoparticulate Doxorubicin" American Association for Cancer Research, AACR (2012)
  • "Probing Drug Exposure-Response Relationships in Inflammatory Bone Loss with Translational Pharmacodynamic Systems Modeling" Bridging Bench and Bedside with Quantitative Model-Based Translational Pharmacology, NYAS (2012)
  • "Towards Enhanced Pharmacodynamic Modeling in Oncology" , University at Buffalo, SUNY (2012)
  • "Cell Signaling Model of CD20 Agonism for Predicting Efficacy of Combination Chemotherapy for non-Hodgkins Lymphoma" , University of Kentucky (2012)
  • "Introduction to Pharmacodynamic Principles" ACDRS Workshop Session 2: Learning Trials: From Discovery to First in Humans, UCSF (2012)
  • "Network-based Analysis for Enhancing PK/PD Modeling in Oncology" Indiana Clinical and Translational Sciences Institute Symposium on Disease and Therapeutic Response Modeling, University of Indiana (2011)
  • "Conceptual Framework of Models Used for PK/PD Modeling of Biologics" AAPS Annual Meeting, AAPS (2011)
  • "PK/PD Systems Analysis: Hands-on Modeling with ADAPT5" AAPS Annual Meeting, AAPS (2011)
  • "Translation of Pharmacodynamics: Concepts and Examples" ISSX 17th North American Meeting, ISSX (2011)
  • "PK/PD Systems Analysis in Translational Research" Applied Pharmaceutical Analysis Annual Meeting, APA (2011)
  • "Bridging PK/PD and Systems Pharmacology Modeling in Oncology" Gordon Research Conference on Drug Metabolism, GRC (2011)
  • "Probing Drug Exposure-Response Relationships Through Translational PK/PD Modeling" 2nd Annual PaSiPhIC, PaSiPhIC (2011)
  • "Pharmacodynamic Modeling of Biomarkers in Drug Development" AAPS NBC, AAPS (2011)
  • "Pharmacokinetics & Pharmacodynamics of Biological Therapeutics" Msc Program, University of Manchester (2011)
  • "Target-mediated Drug Disposition Models: Theory and Parameterization" AAPS NBC, AAPS (2011)
  • "CD20 Receptor Occupancy-driven Cell Signaling Model for Predicting in vivo Combination Chemotherapy" Seminar, Mount Sinai School of Medicine (2011)
  • "Chemotherapy and Translational PK/PD Modeling" Seminar, Merrimack Pharmaceticals (2011)
  • "Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies" 4th APISSX, APISSX (2011)
  • "Introduction to Pharmacodynamic Principles" ACDRS Workshop Session 2: Learning Trials: From Discovery to First in Humans, UCSF (2011)
  • "Theoretical Considerations of the Target-Mediated Disposition of Therapeutic mAbs" ASCPT Annual Meeting, ASCPT (2011)
  • "Small Systems Models for Bridging Exposure-Response Relationships" Drug Safety Workshop: Pharmacological Mechanism-Based Drug Safety Assessment and Prediction, FDA (2011)
  • "Basic Concepts of PK/PD Modeling and Translational Pharmacology" Model-Based Drug Development Workshop, Johnson & Johnson (2010)
  • "Towards Integrating Systems Pharmacology and PK/PD Models" Conference Call, Pfizer (2010)
  • "Modeling and Simulation to Develop Therapeutic Proteins" Annual Meeting of the American College of Clinical Pharmacology, American College of Clinical Pharmacology (2010)
  • "Occupancy-driven Cell Signaling Model of CD20 Agonists to Predict Combination Chemotherapy in Mice" Quantitative and Systems Pharmacology Workshop II, NIH (2010)
  • "Overview of the Importance of Drug Interactions with Biologics" 13th Annual Land O'Lakes Conference (2010)
  • "Whither Systems Pharmacology Modeling?" University at Buffalo, SUNY, Department of Pharmaceutical Sciences (2010)
  • "Pharmacokinetics and Exposure-Response Relationships of Biologics" Delaware Valley Drug Metabolism Discussion Group (2010)
  • "Pharmacodynamic Modeling of Anticancer Agents" Advancing New Therapeutics to Clinical Trials Workshop, SUNY Upstate Cancer Research Institute (2010)
  • "Pharmacokinetics & Pharmacodynamics of Biological Therapeutics" Msc Program, University of Manchester (2010)
  • "Model-Based Approaches for Metabolic Disorders" KSCPT-ASCPT Joint Conference, KSCPT and ASCPT (2009)
  • "PK/PD Modeling and Simulation: History and Basic Principles" Workshop: PK/PD Modeling in Drug Discovery and Translational Research: A Building Block for Quantitative Model-based Drug Development, AAPS (2009)
  • "Postdoctoral Positions in Academia and the NIH" AAPS Annual Meeting, AAPS (2009)
  • "Scaling Pharmacokinetics/Pharmacodynamics from Animal Studies to Humans" AAPS Annual Meeting, AAPS (2009)
  • "Applications of Modeling over the Development Life Cycle of Biologics" American Conference on Pharmacometrics, ACoP (2009)
  • "Overview of Pharmacokinetics and Pharmacodynamics of Biologics" ISSX Annual Meeting, ISSX (2009)
  • "Novel Biomarkers and Disease Models: Why?" ACCP Annual Meeting, ACCP (2009)
  • "Role of Target and Mechanism Biomarkers in Translational Research" AAPS Clinical Pharmacology and Translational Research Webinar, AAPS (2009)
  • "Basic Principles and Approaches to Predicting FIH Doses for MAbs" AAPS National Biotechnology Conference, AAPS (2009)
  • "Integrated Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma" , Pfizer, Inc (2009)
  • "Model-Based Approaches for Metabolic Disorders" , Bristol-Myers Squibb (2009)
  • "Model-Based Approaches for Metabolic Disorders and Biologic Therapeutics" MOSAIC (2009)
  • "Preclinical PK/PD Modeling of Anticancer Agents" UB - Pfizer Strategic Alliance Annual Meeting, Pfizer, Inc (2009)
  • "Receptor-Mediated Drug Disposition of Recombinant Native Interferon-á in Wild-type and Interferon à/áR-/- Knockout Mice" AAPS National Biotechnology Conference, American Association of Pharmaceutical Scientists (2009)
  • "Role of Target and Mechanism Biomarkers in Translational Research" AAPS National Biotechnology Conference, AAPS (2009)
  • "Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Biologics" Current Topics in Drug Metabolism and Pharmacokinetics: Biologics and Transporters - What's New?, North Jersey ACS Drug Metabolism Discussion Group (2009)
  • "Mechanistic Pharmacokinetic/Pharmacodynamic Models" Clinical Pharmacology Review Course, American Society of Clinical Pharmacology and therapeutics (2009)
  • "Population Modeling of Hyperglycemic Clamp and Meal Tolerance Tests in Patients with Type 2 Diabetes Mellitus" ASCPT Annual Meeting, American Society of Clinical Pharmacology and therapeutics (2009)
  • "Integrating Pharmacodynamics into Models of Target-Mediated Drug Disposition" 3rd Roche-Novartis Modeling & Simulation Meeting, Novartis (2009)
  • "Exposure-Response Modeling of Calcium Receptor Antagonist Mediated Stimulation of Parathyroid Hormone Secretion in Rats using an Allosteric Receptor-Binding Model" AAPS Annual Meeting, American Association of Pharmaceutical Scientists (2008)
  • "Physiologically-Based Pharmacokinetic Modeling of Neutral and Charged Nanocomposite Devices in Mice" AAPS Annual Meeting, American Association of Pharmaceutical Scientists (2008)
  • "Selection Between Michaelis-Menten and Target-Mediated Drug Disposition Pharmacokinetic Models" AAPS Annual Meeting, AAPS (2008)
  • "Validity of the Rapid Binding Approximation of a Target-Mediated Drug Disposition Model" AAPS Annual Meeting, American Association of Pharmaceutical Scientists (2008)
  • "Basic Principles in Pharmacology" Ehrlich II - 2nd World Conference on Magic Bullets (2008)
  • "PK-PD Modeling of Aliskiren Effects on Biomarkers of the Renin-Angiotensin System in Humans" Ehrlich II - 2nd World Conference on Magic Bullets (2008)
  • "Biomarkers: An Overview" 11th Annual Land O'Lakes Conference on Drug Metabolism/Applied Pharmacokinetics (2008)
  • "Predicting Pneumonia Scores using an Antimicrobial Drug Exposure/Sensitivity Index and an Artificial Neural Network" 4th International Symposium on Resistant Gram-Positive Infections (2008)
  • "Binding to the Target Ligand: Monoclonal Antibody PK/PD First Principles (Berkeley Madonna Hands-on)" Short Course, AAPS National Biotechnology Conference (2008)
  • "Chemotherapy PK/PD Modeling" UB-Pfizer Annual Research Symposium, Pfizer (2008)
  • "Integrated Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma" Workshop on New Prospects for Cancer Immunotherapy: Integrating Biomarkers in Mathematical Models, Institute for Medical BioMathematics (2008)
  • "Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients" Experimental Biology, American Society of Pharmacology and Experimental therapeutics (2008)
  • "Mapping the relationship between clinical response and an antimicrobial drug exposure/sensitivity index using a neural network" ASCPT Annual Meeting, American Society of Clinical Pharmacology and Therapeutics (2008)
  • "Mechanism based pharmacokinetic/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans" ASCPT Annual Meeting, American Society of Clinical Pharmacology and therapeutics (2008)
  • "Comparison of the performance of likelihood-based methods implemented in NONMEM and MC-PEM/S-ADAPT to account for pharmacokinetic data below the lower limit of quantification" American Conference on Pharmacometrics (2008)
  • "Target-Mediated Disposition of Monoclonal Antibodies: Implications for Mab Development" Groupe de M‚tabolisme et de Pharmacocin‚tique (GMP) (2008)
  • "Mathematical Properties of a Quasi-Equilibrium Model of Target-Mediated Drug Disposition" AAPS Annual Meeting (2007)
  • "Pharmacokinetic/Pharmcodynamic Implications of Receptor Dimerazation and Specific Tissue Distribution in Target-Mediated Drug Disposition Models" AAPS Annual Meeting (2007)
  • "Mechanistic Pharmacokinetic/Pharmacodynamic Models" , Eisai (2007)
  • "Dose versus Response Relationships" , Wyeth (2007)
  • "Binding to the Target Ligand: PK/PD of Monoclonal Antibodies" Sunrise Session, AAPS National Biotechnology Conference (2007)
  • "Chemotherapy PK/PD Modeling" UB-Pfizer Annual Research Symposium, Pfizer (2007)
  • "Mechanistic Pharmacokinetic/Pharmacodynamic Models" Clinical Pharmacology Review Course, American Society of Clinical Pharmacology and therapeutics (2007)
  • "Local parameter sensitivity analysis of selected target-mediated pharmacokinetic models" AAPS Annual Meeting (2006)
  • "Receptor & Target Binding Models" Course in Pharmacokinetic/Pharmacodynamic Modeling, American College of Clinical Pharmacology (2006)
  • "Quantitative Structure-Pharmacokinetic Relationships (QSPKR) using Bayesian Neural Networks" oint SIAM/SMB Conference on the Life Sciences, SIAM (2006)
  • "Approaches to Mechanism-Based PK/PD Modeling in Pediatric Pharmacology" Pediatric Pharmacology and Therapeutics, PPRU NSC Meeting, National Institutes of Health (2006)
  • "Role of Molecular Structure in Determining Pharmacokinetics and Pharmacodynamics" UB-Pfizer Annual Research Symposium, Pfizer (2006)
  • "Target-Mediated Drug Disposition and Dynamics" , University of Georgia (2006)
  • "Modeling Receptor-Mediated PK/PD Systems" , University at Buffalo, SUNY (2006)
  • "K-PD Modeling of Exendin-4 Pharmacodynamics" , Cognigen (2006)
  • "Target-Mediated PK/PD Modeling of Biotechnology Pharmaceuticals" , University at Buffalo, SUNY (2005)
  • "Application of PK/PD Modeling to Expedite the Discovery and Development of Monoclonal Antibodies to Alter Cell Function" , AAPS National Biotechnology Conference (2005)
  • "PK/PD Modeling of Target-Mediated Drug Disposition and Dynamics" 11th BMSR Workshop on Advanced Methods of PK/PD Systems Analysis, University of Southern California (2005)
  • "Application of Non-Deterministic Systems in Clinical Pharmacology" , University at Buffalo, SUNY (2004)
See all (93 more)
Service Activities:
  • Mentoring Committee; Member (2013)
  • SPPS Assessment Committee; Member (2013)
  • Edward Mallinckrodt Jr. Foundation Ad hoc Committee; Member (2013)
  • SPPS Dean Search Committee; Member (2012)
  • PCC Committee; American Association of Pharmaceutical Sciences; Member (2012)
  • Annual Meeting Abstract Screening Committee; ACCP; Reviewer (2012)
  • Annual Meeting Planning Committee; ACCP; Other (2012)
  • Pre-Conference Workshop Planning Committee; ASCPT; Other (2012)
  • Scientific Advisory Board; Certara; Other (2012)
  • Board of Directors; ISOP; Other (2012)
  • American Conference on Pharmacometrics; ISOP; Other (2012)
  • AAPS Nominations Committee; American Association of Pharmaceutical Sciences; Member (2011)
  • Associate Dean Search Committee; Member (2011)
  • Clinical Pharmacology and Translational Research Section; American Association of Pharmaceutical Sciences; Other (2011)
  • Special Interest Group; FIP; Other (2011)
  • Clinical Pharmacology and Translational Research Section; American Association of Pharmaceutical Sciences; Other (2010)
  • Curriculum Committee; Member (2010)
  • Decanal Grievance Committee; Member (2010)
  • ACPE Accreditation Self-Study Subcommittee; Member (2010)
  • Clinical Pharmacology and Translational Research Section; American Association of Pharmaceutical Sciences; Other (2009)
  • Scientific Advisory Board; University of Iowa; Other (2009)
  • Scientific Advisory Board; Biomedical Simulations Resource, USC; Member (2009)
  • Pharmaceutical Sciences Graduate Admissions Committee; Member (2008)
  • AAPS NewsMagazine Content Advisory Committee; American Association of Pharmaceutical Sciences; Member (2008)
  • Center for Protein Therapeutics Management Committee; Member (2008)
  • Clinical Pharmacology Advisory Committee; Food and Drug Administration; Member (2008)
  • Pharmaceutics Graduate Student Awards Committee; Chair, December 2008; Member (2006)
  • Pharmaceutical Sciences Seminar; Other (2006)
  • Pharmaceutical Sciences Faculty Search Committee; Member (2006)
  • Doctor of Pharmacy Admissions Committee; Member (2004)
  • 3rd Annual Post-Doctoral Research Symposium; Reviewer
  • AAPS Biotech 101 Lecturer; American Association of Pharmaceutical Sciences; Other
  • AAPS Graduate Symposium Awards in CPTR/PPDM Committee; American Association of Pharmaceutical Sciences; Other
  • AAPS Symposium Organizer and Moderator; American Association of Pharmaceutical Sciences Systems Pharmacology for the Assessment and Prediction of Adverse Drug Effects; Other
  • Buffalo Pharmaceutical Sciences Symposium; Organized and conducted 2.5-day Conference; Other
  • Community Outreach Activity; CHEMSHARE Hosted CHEMSHARE visit to the Department of Pharmaceutical Sciences, University at Buffalo, SUNY, with the goal of introducing pharmaceutical sciences to local high school chemistry and physics educators.; Other
  • School of Pharmacy & Pharmaceutical Sciences Retreat Committee; Volunteer

School News:
In the Media:

Clinical Specialties:
Clinical Offices:
Insurance Accepted:


Contact Information

431 Kapoor Hall
Buffalo, NY 14214-8033
Phone: (716) 645-2903
Fax: (716) 829-6569
Email: dmager@buffalo.edu


Log in to Update Your Profile
"); pageTracker._trackPageview();